US FDA extends approval of Epclusa (sofosbuvir and velpatasvir) to include treatment of children with hepatitis C virus (HCV)

In the US, this product is now licensed for use in the treatment of HCV in children ages 6 years and older or weighing at least 17 kg with any of the six HCV genotypes. In the UK, it remains licensed only for the treatment of HCV in adults.

Source:

FDA